PTC Therapeutics Raises 2026 Guidance After Q2 Revenue Hits $361M, Sephience Sales Surge
PTCT sits 80% above its 52-week low of $43.175.
Summary
PTC Therapeutics delivered a strong Q2 with total revenue of $361 million, including $239 million in product revenue, driven by Sephience's $151 million (up 21% sequentially). The company raised full-year 2026 total revenue guidance to $1.18-$1.28 billion and product revenue guidance to $850-$950 million, signaling confidence in the ongoing launch. A $50 million milestone from Novartis for the INVEST-HD Phase 3 study added to the top line. The cash position stands at $2.2 billion, providing ample runway. Pipeline progress includes naming PTC303 for Huntington's and myotonic dystrophy, initiating a Phase 1 for PTC612, and planning a Phase 2a for PTC844. This follows the $550 million convertible notes offering completed in June, which strengthened the balance sheet.
At the time of this announcement, PTCT was trading at $77.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $43.18 to $90.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.